Filing Details
- Accession Number:
- 0001127602-12-012001
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-03-28 13:00:00
- Reporting Period:
- 2012-03-26
- Filing Date:
- 2012-03-28
- Accepted Time:
- 2012-03-28 16:15:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 884731 | Ariad Pharmaceuticals Inc | ARIA | Biological Products, (No Disgnostic Substances) (2836) | 223106987 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1542768 | E Maria Cantor | C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139 | Svp, Corporate Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-03-26 | 6,000 | $3.08 | 52,227 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2012-03-26 | 6,000 | $16.00 | 46,227 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-03-27 | 18,000 | $16.23 | 28,227 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-03-26 | 6,000 | $0.00 | 6,000 | $3.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 39,000 | 2018-09-11 | No | 4 | M | Direct |
Footnotes
- Shares were acquired upon the exercise of outstanding stock options at $3.08 per share.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.
- The price reported in Column 4 is a weighted average price. These shares were sold, pursuant to a Rule 10b5-1 plan dated June 25, 2010 as amended on May 13, 2011, in multiple transactions at prices ranging from $16.10 to $16.33, inclusive. The reporting person undertakes to provide to ARIAD Pharmaceuticals, Inc. ("ARIAD"), any security holder of ARIAD, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- Options vest 25% per year on each September 11, of 2009, 2010, 2011 and 2012.
Billionaire Hedge Funds
